摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

山嵛酸钠 | 5331-77-1

中文名称
山嵛酸钠
中文别名
——
英文名称
——
英文别名
——
山嵛酸钠化学式
CAS
5331-77-1
化学式
C22H44NaO2
mdl
——
分子量
363.6
InChiKey
NILBZLMLWALYTH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.51
  • 重原子数:
    25
  • 可旋转键数:
    20
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2915900090

SDS

SDS:b4198c430b0e1aa2743cedfd2f65faa4
查看

制备方法与用途

概述

山嵛酸钠可用作医药合成中间体,例如制备山嵛酸银。山嵛酸银盐的制备方法多种多样,一般采用将山嵛酸碱金属盐溶液与含有银离子的水溶液进行化学沉淀的方法。化学沉淀法通常包括单注沉淀法和双注沉淀法。

首先,在制备山嵛酸银的过程中,需要将山嵛酸转化为皂,如钠皂。钠皂是一种表面活性物质,具有极性基团和非极性基团,因此是两亲性分子,并且具有片状结构。

文献信息

  • [EN] ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES<br/>[FR] FORMULATIONS ORALES DE DÉRIVÉS DE PYRROLIDINE
    申请人:OBSEVA SA
    公开号:WO2015091365A1
    公开(公告)日:2015-06-25
    The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one- O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    本发明涉及固体口服制剂,包括化合物的配方(3Z,5S)-5-(羟甲基)-1-[(2'-甲基-1,1'-联苯基-4-基)羰基]吡咯烷-3-酮-O-甲氧肟,和/或其活性代谢物,并且涉及所述制剂在治疗和/或预防早产、早产、经前痛经和子宫收缩引起的胚胎着床失败中的使用。本发明还涉及其制备方法。
  • BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
    申请人:SENOMYX, INC.
    公开号:US20160376263A1
    公开(公告)日:2016-12-29
    The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.
    本发明涵盖已知用于改变苦味感知的化合物和组合物,以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种:冷却剂;无活性药物成分;活性药用成分;食品添加剂或食品;调味剂或调味增强剂;食品或饮料产品;苦味化合物;甜味剂;苦味剂;酸味调味剂;咸味调味剂;鲜味调味剂;植物或动物产品;已知用于宠物护理产品中的化合物;已知用于个人护理产品中的化合物;已知用于家用产品中的化合物;制药制剂;局部制剂;大麻衍生或与大麻相关的产品;已知用于口腔护理产品中的化合物;饮料;香味、香水或除臭剂;已知用于消费品中的化合物;硅化合物;磨料;表面活性剂;发热剂;吸烟物品;脂肪、油脂或乳化剂;和/或益生菌或补充剂。
  • Compositions Containing Diethanol Amine Esterquats
    申请人:Loeffler Matthias
    公开号:US20110237667A1
    公开(公告)日:2011-09-29
    The invention relates to compositions containing one or more compounds of the formula (1), wherein R 1 CO and R 2 CO are linear or branched saturated acyl groups independent of each other, having 18 to 24 C atoms, and A − is a counter-ion, and the total amount of C 18-23 -alkyl COO groups is 40.0 wt.-% or more, based on all groups R 1 COO— and R 2 COO—. The compositions are, for example, cosmetic, dermatological, or pharmaceutical compositions.
    该发明涉及含有一个或多个式(1)化合物的组合物,其中R1CO和R2CO是线性或支链饱和脂肪酰基,独立于彼此,具有18至24个碳原子,A-是一个对离子,C18-23-烷基COO基团的总量为40.0重量%或更多,基于所有基团R1COO-和R2COO-。这些组合物例如是化妆品、皮肤科或药用组合物。
  • LACTYLATE SYNTHESIS METHODS USING DILACTIDES
    申请人:Botts Jeff B.
    公开号:US20120065422A1
    公开(公告)日:2012-03-15
    The present invention involves a new synthesis route for the formation of lactylates. The method comprises reacting a dilactide with a compound comprising a hydroxy group. This reaction is preferably carried out in the presence of a cation or other source of alkalinity. Preferred compounds comprising a hydroxy group include any fatty acid and fatty acid alcohol (particularly C 1 -C 26 fatty acid chains). Preferred cations include cations of Group I and II metals, with sodium, calcium, and potassium cations being particularly preferred. The inventive reactions proceed much more rapidly than prior art lactylate synthesis reactions, and can be used to form 1-, 2-, 3-, 4-, and 5-lactylates.
    本发明涉及一种用于合成乳酰酸盐的新合成途径。该方法包括将二乳酸酯与含有羟基的化合物发生反应。该反应最好在存在阳离子或其他碱性来源的情况下进行。含有羟基的化合物包括任何脂肪酸和脂肪醇(尤其是碳链为C1-C26的脂肪酸链)。优选的阳离子包括I和II族金属的阳离子,其中特别优选的是钠、钙和钾阳离子。这种创新的反应比现有技术中的乳酰酸盐合成反应快得多,并可用于形成1-、2-、3-、4-和5-乳酰酸盐。
  • ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES
    申请人:ObsEva S.A.
    公开号:US20150164859A1
    公开(公告)日:2015-06-18
    The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    本发明涉及固体口服制剂,包括化合物的配方(3Z,5S)-5-(羟甲基)-1-[(2'-甲基-1,1'-联苯基-4-基)甲酰基]吡咯烷-3-酮-O-甲氧肟,及/或其活性代谢物,并且该制剂在治疗和/或预防早产、早产、痛经和子宫收缩引起的胚胎着床失败中的应用。本发明还涉及其制备方法。
查看更多